PEGFILGRASTIM BIOSIMILARS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Pegfilgrastim Biosimilars Market, By Product (Pegfilgrastim Biosimilars and Pegfilgrastim Reference Product), By Application (Oncology, Chronic Neutropenia, Stem Cell Transplantation, Others), By Route of Administration (Subcutaneous and Intravenous), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Aug 2024
Code : CMI7242
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Concentration and Competitive Landscape

Pegfilgrastim Biosimilars Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Patent Expiries of Pegfilgrastim Biosimilars

Several leading brands of pegfilgrastim have lost their patent protection in the recent past, thus, allowing for manufacturing and sale of affordable biosimilar versions. Neulasta, the pioneering pegfilgrastim therapy, lost exclusivity in the U.S. in 2018. This paved way for multiple biosimilar entrants with pegfilgrastim, which are significantly lower priced than the originator brand. Healthcare systems and patients now have access to cheaper biosimilar options without compromising on quality or efficacy. This has boosted overall adoption of pegfilgrastim and volume growth prospects appear promising as physicians and patients increasingly opt for more affordable biosimilars in place of originator versions. Lower prices ensuing from patent expiry of blockbuster brands can facilitate wider global access and uptake of pegfilgrastim biosimilars.

Key Players Insights